Biotech Stock Live Chat Recap: ASCO & Obesity
BOSTON (TheStreet) -- Welcome to the May Biotech Stock Live Chat. The floor is yours.
I'm here for the next 90 minutes to answer your biotech investing questions and hopefully spark some interactive debate on the hot biotech topics of the day. This chat only works if you participate, so please keep the questions and comments flowing.
My special guest today is Nathan Sadeghi-Nejad, a longtime friend and healthcare analyst/investor for the past 15 years. Nate has been writing a weekly column for TheStreet since February. He's one of the sharpest biotech investors I know so it's a thrill to have him on this live chat to help answer your questions.
The American Society of Clinical Oncology (ASCO) released thousands of cancer drug research abstracts last night in advance of its closely followed annual meeting in two weeks. This, of course, has investors buzzing about cancer drug stocks, so let's discuss Array Biopharma (ARRY), Onyx Pharma (ONXX), Seattle Genetics (SGEN), Ariad Pharma (ARIA) and Celldex Therapeutics (CLDX), or any other ASCO-related stock that interests you. If cancer isn't your thing, then how about more discussion of obesity drugs stocks Arena Pharmaceuticals (ARNA) and Vivus (VVUS), both of which are gearing up for FDA drug approval decisions in the next two months. Or, we could talk about Vertex Pharmaceuticals (VRTX) and its exciting cystic fibrosis drug franchise which helped boost the company's market cap by billions of dollars last week. --Written by Adam Feuerstein in Boston.>To contact the writer of this article, click here: Adam Feuerstein. >To follow the writer on Twitter, go to http://twitter.com/adamfeuerstein. >To submit a news tip, send an email to: tips@thestreet.com. Follow TheStreet on Twitter and become a fan on Facebook.
Select the service that is right for you!
COMPARE ALL SERVICESAction Alerts PLUS
TRY IT FREEJim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
Product Features:
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Dividend Stock Advisor
TRY IT FREENew! $49.95/yr
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
Product Features:
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Stocks Under $10
TRY IT FREEDavid Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.
Product Features:
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
- Weekly roundups
Real Money
TRY IT FREE24/7 market commentary from Jim Cramer and 20+ veteran Wall Street gurus. Get access to the latest trading ideas on stocks, options, and ETFs as well as a real-time forum to see the pros exchanging their investment ideas.
Product Features:
- Jim Cramer + 20 Wall Street pros
- Intraday commentary & news
- Real-time trading forum
- Actionable trade ideas
Real Money Pro
TRY IT FREEAll of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
Product Features:
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Options Profits
TRY IT FREEOur options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
Product Features:
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV
